Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study

Published: 13 October 2023| Version 1 | DOI: 10.17632/hpc4rpv6j8.1
Contributor:
Joslyn Kirby

Description

Supplementary appendix for an article "Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study" for The Journal of the American Academy of Dermatology

Files

Categories

Hidradenitis Suppurativa

Licence